Sean Bohen, MD, PhD
The PARP inhibitor olaparib (Lynparza) demonstrated a statistically significant and clinically meaningful improvement in objective response rate in patients with BRCA
-mutant ovarian cancer who have relapsed on at least 2 prior lines of therapy, according to topline findings of the confirmatory phase III SOLO-3 trial (NCT02282020).1
- Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer. AstraZeneca. Published December 20, 2018. https://bit.ly/2Si6yKx?rel=0" . Accessed December 20, 2018.
- Kaufman B, Shapira-Frommer R, Schmultzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244-250. doi:10.1200/JCO.2014.56.2728.
- Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199-203. doi: 10.1016/j.ygyno.2015.12.020.
... to read the full story